|
Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations - 5 Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations - 5 conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations - 5 Clinical research trials and Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations - 5 healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations - 5. Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations - 5 Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations - 5 clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations - 5 condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations - 5  Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations - 5
Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations - 5
For Condition: Heroin Dependence
Status: Completed
Sponsor(s): National Institute on Drug Abuse (NIDA) ,
Synopsis: Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations
Details: Participants were inducted on either liquid or tablet buprenorphine, in a double-blind, double-dummy manner. They each reached a steady state by the second week, and were scheduled to have blood draws in weeks 3, 4, 7, 8, 11, 12, 15, and 16.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind, Uncontrolled
Minimum Age/Maximum Age: 21 Years/50 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: M/F ages 21-50. Opiate dependence according to DSM-IV criteria. Currently enrolled in the outpatient protocol comparing liquid and tablet formulations of Buprenorphine. Agreeable to conditions of study and signed informed consent. Exclusion Criteria: Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.
Total Enrollment: 0
Location and Contact Information:
Overall Study Official:
WalterLing, Principal Investigator, Friends Research Institute
Friends Research Institute
Los Angeles, California, 90025
United States
Additional Information:
Study ID Numbers: NIDA-09260-5; P50-09260-5
Study Start Date:
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000302
Other Heroin Dependence Studies:
1. Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification - 1
2. Treatment Efficacy for Drug Abuse and AIDS Prevention - 1
3. Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3
4. PK0496 Pharmacokinetics of Buprenorphine - 10
5. Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1(1) - 1
Related Studies:
Other Heroin Dependence Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations - 5
|
|
|
|
|
|
|
|
